Citations

Showing 10 of 108083 citations.

Combined heart-liver transplantation practices survey in North America: Evaluation and organ listing practices
Shingina, Alexandra , Chadha, Ryan , Lim, Nicholas , Pillai, Anjana , Vodkin, Irene, Montenovo, Martin I. , Heller, Theo , Yardeni, David , Ganger, Daniel , Montenovo, Martin , Chadha, Ryan , Lim, Nicholas , Heller, Theo

Mayo Clinic

Liver Transplantation | February 6, 2023 | Volume: 29 | Issue: 6 | Pages: 591-597

10.1097/lvt.0000000000000079 | PMID 36745932 Get It

We conducted a web-based survey to characterize liver transplant (LT) evaluation and listing practices for patients being evaluated for combined heart-liver transplantation (CHLT), with a specific emphasis on patients with congenital heart disease (CHD), around transplant centers in North America. Very few protocols for liver evaluation and listing in patients undergoing combined heart-liver transplantation are published, and no guidelines currently exist on this topic. A subject of intense debate in the transplant community is the decision of which patients with CHD and liver disease benefit from CHLT compared with heart transplantation. A focus group from the American Society of Transplantation Liver-Intestine Community of Practice Education Subcommittee developed a web-based survey that included questions (1) respondee demographic information; (2) LT evaluation practices in CHLT; (3) liver organ listing practices in CHLT, and (4) 4 clinical vignettes with case-based scenarios in CHLT liver listings among CHD patients who underwent Fontan palliation. The survey was distributed to medical and surgical LT program directors of 47 centers that had completed at least 1 CHLT up to July 2021 in the US and the University of Toronto, Canada. The survey had an excellent 83% response rate (87% for centers that completed at least 1 CHLT in the past 5 y). Total 66.7% used transjugular liver biopsy with HVPG measurements, 30% used percutaneous liver biopsy with no consensus on the use of a fibrosis staging system, 95% mandated contrasted cross-sectional imaging, and 65% upper endoscopy. The following isolated findings evaluation mandated CHLT listing: isolated elevated HVPG (61.5%); the presence of portosystemic collaterals on imaging (67.5%); the endoscopic presence of esophageal or gastric varices (75%), and the presence of HCC (80%), whereas the majority of centers did not feel that the presence of isolated splenomegaly (100%), thrombocytopenia (81.6%), endoscopic findings of portal hypertensive gastropathy (66.7%), or highly sensitized patients (84.6%) justified CHLT. In our survey of North American centers that had performed at least 1 CHLT in the past 5 years, we observed heterogeneity in practices for both evaluation and listing protocols in these patients.
Myosin post-translational modifications and function in the presence of myopathy-linked truncating MYH2 mutations
Sonne, Alexander, Domínguez‐González, Cristina , Andersen, Jesper L. , Milone, Margherita , Ochala, Julien , Ochala, Julien , Peverelli, Lorenzo , Hernández‐Laín, Aurelio , Beggs, Alan H.

Mayo Clinic

American Journal of Physiology-Cell Physiology | February 6, 2023 | Volume: 324 | Issue: 3 | Pages: C769-C776

10.1152/ajpcell.00002.2023 | PMID 36745529 Get It

Congenital myopathies are a vast group of genetic muscle diseases. Among the causes are mutations in the MYH2 gene resulting in truncated type IIa myosin heavy chains (MyHCs). The precise cellular and molecular mechanisms by which these mutations induce skeletal muscle symptoms remain obscure. Hence, in the present study, we aimed to explore whether such genetic defects would alter the presence as well as the post-translational modifications of MyHCs and the functionality of myosin molecules. For this, we dissected muscle fibers from four myopathic patients with MYH2 truncating mutations and from five human healthy controls. We then assessed 1) MyHCs presence/post-translational modifications using LC/MS; 2) relaxed myosin conformation and concomitant ATP consumption with a loaded Mant-ATP chase setup; 3) myosin activation with an unloaded in vitro motility assay; and 4) cellular force production with a myofiber mechanical setup. Interestingly, the type IIa MyHC with one additional acetylated lysine (Lys35-Ac) was present in the patients. This was accompanied by 1) a higher ATP demand of myosin heads in the disordered-relaxed conformation; 2) faster actomyosin kinetics; and 3) reduced muscle fiber force. Overall, our findings indicate that MYH2 truncating mutations impact myosin presence/functionality in human adult mature myofibers by disrupting the ATPase activity and actomyosin complex. These are likely important molecular pathological disturbances leading to the myopathic phenotype in patients.
Impact of time to chest closure on early and late survival in adults with delayed sternal closure
Crestanello, Juan A. , Greason, Kevin L. , Elsisy, Mohamed, Lahr, Brian D. , Bagameri, Gabor, Daly, Richard C. , Stulak, John M., Schaff, Hartzell V. , Elsisy, Mohamed F. , Daly, Richard , Dearani, Joseph, Schaff, Hartzell , Crestanello, Juan A , Dearani, Joseph A.

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | February 6, 2023 | Volume: 63 | Issue: 2 | Pages: No page available

10.1093/ejcts/ezad044 | PMID 36749008 Get It

Abstract OBJECTIVES Delayed sternal closure (DSC) after cardiac surgery is a temporizing measure to address coagulopathy or haemodynamic instability after cardiac surgery. We sought to study: (i) indications and temporal trends for DSC, (ii) factors associated with time to chest closure and (iii) its impact on short-term and long-term outcomes. METHODS From January 2007 to December 2017, 494 patients (median age 67 years, 66% males) required DSC after cardiac surgery. Medical records were reviewed for indications, risk factors, time to DSC and outcomes. Multivariable Cox regression via landmark analysis of 486 5-day survivors was used to investigate the impact of time to chest closure on early and late survival. RESULTS Coagulopathy and haemodynamic instability were the most common indications. Median time to chest closure was 2 days. Pre-/intraoperative extracorporeal membranous oxygenation, severe right ventricular dysfunction and diabetes mellitus were associated with longer time to chest closure. Longer time to closure was associated with increased risk of operative complications and operative mortality, but did not have a statistically significant association with late mortality. Increasing age, pulmonary hypertension and a greater number of prior sternotomies were also found to be associated with overall mortality. CONCLUSIONS While longer time to chest closure was associated with increased rates of operative complications and operative mortality, it did not reveal a statistically significant association with long-term survival.
Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities
Mahmoud, Ahmed , Nabavizadeh, Reza , Pessoa, Rodrigo Rodrigues , Garg, I. D. , Orme, Jacob J. , Costello, Brian A. , Cheville, John C. , Mahmoud, Ahmed M , Rodrigues Pessoa, Rodrigo, Garg, Ishita, Lucien, Fabrice , Lucien, Fabrice

Mayo Clinic

The Oncologist | February 6, 2023 | Volume: 28 | Issue: 4 | Pages: 297-308

10.1093/oncolo/oyac263 | PMID 36745503 Get It

AbstractRenal cell carcinoma (RCC) is among the top 10 most common cancers in both men and women with an estimated 75 000 cases each year in the US. Over the last decade, the therapeutic landscape for patients with metastatic RCC has significantly evolved, with immunotherapy emerging as the new front-line therapy. Despite significant improvement in toxicity profile and survival outcomes, key concerns such as patient selection, treatment sequencing, and intrinsic and acquired resistance remain unresolved. Emerging options such as antibody-based therapeutics (eg, anti-CD70, anti-CA9, and anti-ENPP3) are being explored in clinical trials for patients with cancer resistant or refractory to current immunotherapies. Despite positive results for hematological cancers, breast cancer, and more recently bladder cancer, most antibody-based therapies failed to improve the outcomes in patients with advanced RCC. This underscores the need to understand the underlying causes of failed responses to this treatment class, which will ultimately support the rational design of more effective and tolerable treatments. In this review, we summarize the evolving landscape of RCC therapeutics and describe recent clinical trials with emerging antibody-based therapeutics. We also describe the challenges that need to be overcome for the successful creation of therapeutic antibodies for treating RCC.
Left dural‐based mass in a 62‐year‐old female
Elhalaby, Rofyda , Kavran, Christina A., Vaubel, Rachael A. , Villalobos, Maria Adelita Vizcaino, Elhalaby, Rofyda Essam , Vaubel, Rachael A , Vizcaino Villalobos, Maria Adelita, Kavran, Christina A.

Mayo Clinic

Brain Pathology | February 6, 2023 | Volume: 33 | Issue: 4 | Pages: No page available

10.1111/bpa.13145 | PMID 36745463 Get It

Palpitations and Shortness of Breath—Just a “Bump in the Road” or Something More?
Goldschlager, Nora , Jhawar, Nikita , Kusumoto, Fred

Mayo Clinic

JAMA Internal Medicine | February 6, 2023 | Volume: 183 | Issue: 4 | Pages: 364

10.1001/jamainternmed.2022.6359 | PMID 36745415 Get It

A previously healthy person in their 60s with progressive shortness of breath and fatigue for the past 6 months presented to the emergency department with palpitations and shortness of breath. What is your diagnosis?
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis
Vanood, Aimen , Harahsheh, Ehab , Baqal, Omar , Baqal, Omar J

Mayo Clinic

JAMA Neurology | February 6, 2023 | Volume: 80 | Issue: 4 | Pages: 415

10.1001/jamaneurol.2022.5197 | PMID 36745432 Get It

This case report describes a patient with status epilepticus and neuroimaging features of fleeting T2 fluid-attenuated inversion recovery hyperintense lesions on magnetic resonance imaging.
A phase 1 open‐label trial evaluating focused ultrasound unilateral anterior thalamotomy for focal onset epilepsy
Krishna, Vibhor , Mindel, Jesse, Sammartino, Francesco , Gompel, Jamie J. Van , Fountain, Nathan B. , Fisher, Robert S. , Van Gompel, Jamie J , Fountain, Nathan , Fisher, Robert , Block, Cady K. , Dwivedi, Alok

Mayo Clinic

Epilepsia | February 6, 2023 | Volume: 64 | Issue: 4 | Pages: 831-842

10.1111/epi.17535 | PMID 36745000 Get It

AbstractObjectiveFocused ultrasound ablation (FUSA) is an emerging treatment for neurological and psychiatric diseases. We describe the initial experience from a pilot, open‐label, single‐center clinical trial of unilateral anterior nucleus of the thalamus (ANT) FUSA in patients with treatment‐refractory epilepsy.MethodsTwo adult subjects with treatment‐refractory, focal onset epilepsy were recruited. The subjects received ANT FUSA using the Exablate Neuro (Insightec) system. We determined the safety and feasibility (primary outcomes), and changes in seizure frequency (secondary outcome) at 3, 6, and 12 months. Safety was assessed by the absence of side effects, that is, new onset neurological deficits or performance deterioration on neuropsychological testing. Feasibility was defined as the ability to create a lesion within the anterior nucleus. The monthly seizure frequency was compared between baseline and postthalamotomy.ResultsThe patients tolerated the procedure well, without neurological deficits or serious adverse events. One patient experienced a decline in verbal fluency, attention/working memory, and immediate verbal memory. Seizure frequency reduced significantly in both patients; one patient was seizure‐free at 12 months, and in the second patient, the frequency reduced from 90–100 seizures per month to 3–6 seizures per month.SignificanceThis is the first known clinical trial to assess the safety, feasibility, and preliminary efficacy of ANT FUSA in adult patients with treatment‐refractory focal onset epilepsy.
Sleep-related predictors of cognition among adults with chronic insomnia and heart failure enrolled in a randomized controlled trial of cognitive behavioral therapy for insomnia
O’Connell, Meghan , Geer, Jacqueline H. , Conley, Samantha , Redeker, Nancy S. , Yaggi, Henry Klar , Jeon, Sangchoon

Mayo Clinic

Journal of Clinical Sleep Medicine | February 6, 2023 | Volume: 19 | Issue: 6 | Pages: 1073-1081

10.5664/jcsm.10498 | PMID 36740924 Get It

Documentation of polysomnographic and home sleep apnea test interpretations: room for improvement?
Herberts, Michelle , Herberts, Michelle B, Morgenthaler, Timothy I.

Mayo Clinic

Journal of Clinical Sleep Medicine | February 6, 2023 | Volume: 19 | Issue: 6 | Pages: 1043-1049

10.5664/jcsm.10460 | PMID 36740919 Get It